The drug currently sweeping through the world’s prescription markets as a treatment for diabetes and obesity may turn out to do something its manufacturer never quite designed it for. In July 2025, a research team led by Michael J. Corley of UC San Diego, with Varun Dwaraka of the epigenetic-testing company TruDiagnostic as a key collaborator, published a preprint paper on medRxiv reporting the results of a randomized, double-blind, placebo-controlled clinical trial in which 108 adults received either weekly semaglutide injections — the active ingredient in Ozempic and Wegovy — or placebo, for 32 weeks. The work was subsequently published in Nature Communications in 2026. At the end of the trial, the participants who had received semaglutide showed measurable reductions in biological age across multiple validated epigenetic clocks, with an average reduction of approximately 3.1 years on the most-cited indices and up to 5 years on the most sensitive clocks. The placebo group showed no comparable changes. The trial is, by the researchers’ own characterization, the first direct clinical-trial evidence that a GLP-1 receptor agonist can modulate validated biomarkers of human aging.
According to the University of California’s press release on the study, the trial population was specifically people with HIV-associated lipohypertrophy — a condition in which excess fat builds up around the abdomen, and which is known to be accompanied by accelerated biological aging, persistent low-grade inflammation, and elevated cardiovascular risk. The choice of this population was deliberate. People with HIV-associated lipohypertrophy exhibit biological aging patterns substantially in excess of their chronological age, which makes them an unusually sensitive population for detecting any age-slowing effects of a candidate intervention. The 108 participants were randomized to either weekly semaglutide injections or matching placebo, with blood samples collected at baseline and at 32 weeks to enable detailed epigenetic age measurements before and after the intervention.
What the epigenetic clocks measured
The biological-age measurements in the trial were not based on subjective health indicators or simple physical metrics. They were based on DNA methylation patterns in the participants’ blood cells — chemical modifications that accumulate on the DNA over time and that have been validated across multiple independent studies as reliable indicators of biological age, mortality risk, and the rate at which a person’s body is aging. The trial used several different epigenetic clocks in parallel, each capturing slightly different aspects of the aging process. The first-generation clocks (Horvath clock and similar) measure cumulative biological age. The second-generation clocks (PhenoAge, GrimAge, PCGrimAge) are tuned to predict morbidity and mortality outcomes. The third-generation DunedinPACE clock measures the current rate at which aging is occurring, rather than the cumulative damage to date.
Per the original Corley et al. preprint on medRxiv, semaglutide produced the most pronounced effects on second-generation clocks predictive of morbidity and mortality risk, and on the third-generation DunedinPACE measure of biological aging rate, which slowed by approximately 9 percent in the treatment group. The first-generation clocks showed smaller but still measurable effects. The convergence of effects across multiple independent epigenetic measures is what gives the trial result its weight — semaglutide was not modulating a single biomarker that might have been a statistical artifact; it was modulating several at once, including the ones with the strongest established links to disease and mortality outcomes.
What the mechanism might be
The pathways by which semaglutide produces these aging-slowing effects are not yet fully characterized, but several converging hypotheses are now under investigation. The Corley team’s preprint identifies three plausible mechanisms. The first is reduced systemic inflammation — semaglutide treatment is associated with substantial reductions in inflammatory cytokines, and chronic low-grade inflammation is one of the central drivers of accelerated biological aging in the broader geroscience literature. The second is reduced visceral adipose tissue — the deep abdominal fat that secretes inflammatory and metabolically active molecules, and that has been independently linked to accelerated aging trajectories. The third is the modulation of what the authors call “obesogenic epigenetic memory” — the persistent epigenetic marks that obesity leaves on cells even after weight loss has occurred, and that may continue to drive accelerated aging long after the metabolic indicators have normalized.
As reported in Singularity Hub’s coverage of the trial, the magnitude of the semaglutide effect is comparable to the effects observed in the CALERIE trial of caloric restriction — the gold-standard randomized human trial of slowing biological aging through dietary intervention. The CALERIE participants, on approximately 12 percent caloric restriction for two years, showed approximately 2 to 3 percent slowing of biological aging on the DunedinPACE clock. The Corley semaglutide participants, on 32 weeks of weekly injections, showed approximately 9 percent slowing on the same clock. The convergence with the dietary-intervention literature suggests that semaglutide may be operating through some of the same metabolic pathways that caloric restriction does — reduced inflammation, reduced visceral fat, improved insulin sensitivity, modulation of mitochondrial function — but through pharmacological rather than dietary means.
What the trial does not establish
Honest framing requires several caveats. The study population was specifically people with HIV-associated lipohypertrophy, who exhibit elevated baseline biological aging — meaning the magnitude of the effect in a general adult population without accelerated-aging conditions is not yet established and could be smaller. The biological-age measurements are based on epigenetic biomarkers, which are well-validated as predictors of aging-related outcomes but are not themselves clinical outcomes. A 3-year reduction in epigenetic age is meaningful in terms of what it predicts about future mortality and disease risk, but it is not the same as a 3-year extension of measured lifespan, which would require multi-decade follow-up to confirm.
The trial also cannot fully disentangle the question of whether semaglutide is slowing aging directly, slowing aging indirectly through its effects on weight and metabolism, or both. As reported in Pharmaceutical Executive’s coverage of the trial, the participants who showed the largest reductions in biological age also tended to show the largest improvements in visceral fat, inflammatory markers, and metabolic indicators — suggesting that the age-slowing effect may be mediated by the metabolic improvements rather than being independent of them. Whether this distinction matters clinically depends on what one cares about: if the goal is slowing biological aging through any available means, the mechanism is less important than the outcome. If the goal is identifying a “pure” geroscience intervention that targets aging directly rather than indirectly, semaglutide may turn out to be more accurately described as an exceptionally effective metabolic drug whose age-slowing effects are downstream of its primary action.
Where this fits in the broader picture
The Corley trial is one of several recent findings positioning GLP-1 receptor agonists as candidate longevity drugs. The SELECT trial, published in 2024, followed 17,604 overweight people with cardiovascular disease for several years and found that semaglutide reduced major cardiovascular events by approximately 20 percent — an effect substantially larger than would be predicted by weight loss alone. A pilot study published in npj Aging in 2025 found that 42 percent of HIV-positive participants with metabolic dysfunction-associated steatotic liver disease showed reduced DunedinPACE aging rates on semaglutide. Additional trials in non-HIV populations, including the recently launched study at Zhejiang University comparing semaglutide and tirzepatide in obese adults without other conditions, are now underway to address the generalisability question that the 2025 Corley trial cannot answer on its own.
The next several years of GLP-1 research will determine whether semaglutide and similar drugs become routinely prescribed not just for diabetes and obesity but for the underlying biology of aging itself. If the early findings hold up across broader populations, the implications would be substantial: a class of drugs already approved by the FDA, already covered by major health insurers, already taken by an estimated 6 to 12 percent of US adults at last count, may turn out to be among the first medications in human history to formally extend healthspan in addition to treating the specific conditions for which they were originally designed. The 2025 Corley study is one piece of evidence in a longer chain of investigation, and the broader case is still being built. The biological signal, however, is now strong enough that the question is no longer whether to investigate semaglutide as a longevity drug, but how quickly the necessary trials can be designed, funded, and completed.
